Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Effect of 3'UTR RET Variants on RET mRNA Secondary Structure and Disease Presentation in Medullary Thyroid Carcinoma.

Ceolin L, Romitti M, Rodrigues Siqueira D, Vaz Ferreira C, Oliboni Scapineli J, Assis-Brazil B, Vieira Maximiano R, Dias Amarante T, de Souza Nunes MC, Weber G, Maia AL.

PLoS One. 2016 Feb 1;11(2):e0147840. doi: 10.1371/journal.pone.0147840. eCollection 2016.

2.

Induction of apoptosis and autophagy in metastatic thyroid cancer cells by valproic acid (VPA).

Xu Y, Xu D, Zhu SJ, Ye B, Dong JD, Zhang YL, Zhang Y.

Int J Clin Exp Pathol. 2015 Jul 1;8(7):8291-7. eCollection 2015.

3.

Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer.

Ji JH, Oh YL, Hong M, Yun JW, Lee HW, Kim D, Ji Y, Kim DH, Park WY, Shin HT, Kim KM, Ahn MJ, Park K, Sun JM.

PLoS Genet. 2015 Aug 21;11(8):e1005467. doi: 10.1371/journal.pgen.1005467. eCollection 2015 Aug.

4.

Selective use of vandetanib in the treatment of thyroid cancer.

Fallahi P, Di Bari F, Ferrari SM, Spisni R, Materazzi G, Miccoli P, Benvenga S, Antonelli A.

Drug Des Devel Ther. 2015 Jul 3;9:3459-70. doi: 10.2147/DDDT.S72495. eCollection 2015. Review.

5.

Mouse models of thyroid cancer: A 2015 update.

Kirschner LS, Qamri Z, Kari S, Ashtekar A.

Mol Cell Endocrinol. 2016 Feb 5;421:18-27. doi: 10.1016/j.mce.2015.06.029. Epub 2015 Jun 27.

PMID:
26123589
6.

A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.

Platt A, Morten J, Ji Q, Elvin P, Womack C, Su X, Donald E, Gray N, Read J, Bigley G, Blockley L, Cresswell C, Dale A, Davies A, Zhang T, Fan S, Fu H, Gladwin A, Harrod G, Stevens J, Williams V, Ye Q, Zheng L, de Boer R, Herbst RS, Lee JS, Vasselli J.

BMC Cancer. 2015 Mar 23;15:171. doi: 10.1186/s12885-015-1146-8.

7.

Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG; American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma.

Thyroid. 2015 Jun;25(6):567-610. doi: 10.1089/thy.2014.0335.

PMID:
25810047
8.

Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.

Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M, Funahashi Y.

J Thyroid Res. 2014;2014:638747. doi: 10.1155/2014/638747. Epub 2014 Sep 10.

9.

Medical management of metastatic medullary thyroid cancer.

Maxwell JE, Sherman SK, O'Dorisio TM, Howe JR.

Cancer. 2014 Nov 1;120(21):3287-301. doi: 10.1002/cncr.28858. Epub 2014 Jun 18. Review.

10.

Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer.

Lacouture ME, Ciccolini K, Kloos RT, Agulnik M.

Thyroid. 2014 Sep;24(9):1329-40. doi: 10.1089/thy.2013.0700. Epub 2014 Jul 15. Review.

11.

2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer.

Elisei R, Alevizaki M, Conte-Devolx B, Frank-Raue K, Leite V, Williams GR.

Eur Thyroid J. 2013 Jan;1(4):216-31. doi: 10.1159/000346174. Epub 2012 Dec 19.

12.

Thyroid Cancer: Role of RET and Beyond.

Carlomagno F.

Eur Thyroid J. 2012 Apr;1(1):15-23. doi: 10.1159/000336975. Epub 2012 Mar 28. Review.

13.

Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma.

Wang N, Xu D, Sofiadis A, Höög A, Vukojević V, Bäckdahl M, Zedenius J, Larsson C.

J Clin Endocrinol Metab. 2014 Aug;99(8):E1571-9. doi: 10.1210/jc.2014-1158. Epub 2014 Apr 23.

14.

Novel insight into mutational landscape of head and neck squamous cell carcinoma.

Gaykalova DA, Mambo E, Choudhary A, Houghton J, Buddavarapu K, Sanford T, Darden W, Adai A, Hadd A, Latham G, Danilova LV, Bishop J, Li RJ, Westra WH, Hennessey P, Koch WM, Ochs MF, Califano JA, Sun W.

PLoS One. 2014 Mar 25;9(3):e93102. doi: 10.1371/journal.pone.0093102. eCollection 2014.

15.

Deregulation of microRNA expression in thyroid tumors.

Yuan ZM, Yang ZL, Zheng Q.

J Zhejiang Univ Sci B. 2014 Mar;15(3):212-24. doi: 10.1631/jzus.B1300192. Review.

16.

Sorafenib in metastatic thyroid cancer: a systematic review.

Thomas L, Lai SY, Dong W, Feng L, Dadu R, Regone RM, Cabanillas ME.

Oncologist. 2014 Mar;19(3):251-8. doi: 10.1634/theoncologist.2013-0362. Epub 2014 Feb 21. Review.

17.

Translational research in endocrine surgery.

Sherman SK, Howe JR.

Surg Oncol Clin N Am. 2013 Oct;22(4):857-84. doi: 10.1016/j.soc.2013.06.012. Epub 2013 Jul 26. Review.

18.

Cabozantinib in progressive medullary thyroid cancer.

Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI.

J Clin Oncol. 2013 Oct 10;31(29):3639-46. doi: 10.1200/JCO.2012.48.4659. Epub 2013 Sep 3. Erratum in: J Clin Oncol. 2014 Jun 10;32(17):1864.

19.

A differential diagnosis of inherited endocrine tumors and their tumor counterparts.

Toledo SP, Lourenço DM Jr, Toledo RA.

Clinics (Sao Paulo). 2013 Jul;68(7):1039-56. doi: 10.6061/clinics/2013(07)24. Review.

20.

Improvement of radioimmunotherapy using pretargeting.

Frampas E, Rousseau C, Bodet-Milin C, Barbet J, Chatal JF, Kraeber-Bodéré F.

Front Oncol. 2013 Jun 20;3:159. doi: 10.3389/fonc.2013.00159. eCollection 2013.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk